The diagnostic value of long noncoding RNAs as a biomarker for in-stent restenosis in patients with coronary heart disease: A systematic review and meta-analysis of diagnostic test accuracy studies

长链非编码RNA作为冠心病患者支架内再狭窄生物标志物的诊断价值:诊断试验准确性研究的系统评价和荟萃分析

阅读:1

Abstract

BACKGROUND: The diagnostic utility of long noncoding RNAs (lncRNAs) in detecting in-stent restenosis (ISR) among coronary heart disease (CHD) patients has drawn significant research interest. Despite this attention, however, only a limited number of lncRNAs have been translated into clinical applications. This study seeks to systematically assess the diagnostic accuracy of lncRNAs for identifying ISR in the CHD population. METHODS: This meta-analysis was registered with PROSPERO (CRD420251105086).A systematic search was performed across PubMed, Web of Science, EMBASE, Wanfang, CNKI, and VIP to retrieve studies evaluating the diagnostic accuracy of lncRNAs for ISR in CHD patients, with a publication cutoff of July 2025. The diagnostic performance of lncRNAs was assessed using pooled sensitivity and specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), summary receiver operating characteristic curve area (AUC), and diagnostic odds ratio (DOR). Statistical analyses were conducted using STATA 14.0 software. RESULTS: A total of 7 studies involving 1020 patients were included in the analysis. The diagnostic performance of lncRNAs for identifying ISR in CHD patients was evaluated using sensitivity, specificity, PLR, NLR, DOR, and AUC. Pooled estimates revealed a sensitivity of 0.81 (95% CI: 0.75-0.86) and specificity of 0.79 (95% CI: 0.75-0.82). Corresponding PLR, NLR, and DOR were 3.8 (95% CI: 3.2-4.6), 0.24 (95% CI: 0.18-0.32), and 16 (95% CI: 11-24), respectively. The summary AUC was 0.86 (95% CI: 0.83-0.89).Subgroup analyses demonstrated significantly higher diagnostic accuracy for lncRNAs in patients with follow-up times ≤ 12 months (AUC: 0.88) compared to those with follow-up times > 12 months (AUC: 0.81). Studies with sample sizes > 100 cases exhibited superior performance (AUC: 0.89) versus those with ≤ 100 cases (AUC: 0.84). Serum-based lncRNA measurements showed a significantly higher AUC (0.89) than non-serum specimens (0.83). Diagnostic performance also varied by detection method, with RT-PCR demonstrating a higher AUC (0.87) compared to RT-qPCR (0.86). Notably, down-regulated lncRNAs exhibited better diagnostic utility (AUC: 0.86) than up-regulated lncRNAs (AUC: 0.82). CONCLUSION: LncRNAs demonstrate substantial diagnostic accuracy for detecting ISR in CHD patients. Nevertheless, further large-scale, prospective studies are required to validate their clinical utility and clarify their underlying molecular mechanisms.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。